CD8A and non-small cell lung carcinoma: In the NSCLC cases receiving anti-PD-1 therapy, the CR/PR group had higher levels of PD-L1 expression, TMB, PD-1+ Tils infiltration, and CD8+ T cell infiltration (Fig. 5), and most cases in this group have high levels of multiple biomarkers at the same time.